Evolent Health Inc. agreed to acquire Magellan Specialty Health from Centene Corp. in a deal worth up to $750 million. The companies also reported a strategic partnership to continue and expand Centene’s relationship with Magellan Specialty Health. Read More
Sema4 Holdings Corp., Illumina Inc. and Pear Therapeutics Inc. joined a growing list of med-tech companies responding to what Pear CEO Corey McCann called a “challenging macroenvironment” by spinning off, selling or shuttering non-core lines of business and slimming payroll. Read More
As China seeks to be more independent in medical device development, authorities have released several guidelines to enhance the quality of its medical devices, as well as accelerate their registration. Read More
The U.S. FDA has finalized a rewritten draft guidance for Section 522 postmarket surveillance studies, a policy that carries a new level of stringency regarding how these studies are conducted. The final guidance calls for all subjects in such a study to be enrolled within 24 months, a deadline some in industry argued might prove unduly burdensome in some instances. Read More
Digital health remains a primary driver of med-tech partnerships and mergers, accounting for 67.3% of all deal activity and 49.9% of the completed M&As in 2022. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Heartvista, Seegene, Siemens Healthineers, Varian. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aidoc Medical. Read More
